2024 NOSCM | Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

2024 NOSCM | Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Overview

NA

Target Audience

NA

This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.

Faculty

Cesar A. Santa-Maria, MD, MSCI

Date of Release

May 14th, 2025